초록 ▼

A circuit includes a drive transistor coupled between an output and a first potential, a constant current circuit coupled between the gate of the drive transistor and a second potential, and a compensation circuit coupled between the gate of the drive transistor and the first potential. The constant

A circuit includes a drive transistor coupled between an output and a first potential, a constant current circuit coupled between the gate of the drive transistor and a second potential, and a compensation circuit coupled between the gate of the drive transistor and the first potential. The constant current circuit draws a current from the gate of the drive transistor to the second potential that is substantially independent of process and temperature variations, and therefore turns on the drive transistor at a constant rate, regardless of process and temperature variations. The compensation circuit draws a small current from the gate of the drive transistor to the first potential that is dependent upon process and temperature variations of the drive transistor, and therefore reduces the discharge rate of the gate of the drive transistor according to process and temperature variations of the drive transistor.

대표청구항 ▼

A circuit includes a drive transistor coupled between an output and a first potential, a constant current circuit coupled between the gate of the drive transistor and a second potential, and a compensation circuit coupled between the gate of the drive transistor and the first potential. The constant

A circuit includes a drive transistor coupled between an output and a first potential, a constant current circuit coupled between the gate of the drive transistor and a second potential, and a compensation circuit coupled between the gate of the drive transistor and the first potential. The constant current circuit draws a current from the gate of the drive transistor to the second potential that is substantially independent of process and temperature variations, and therefore turns on the drive transistor at a constant rate, regardless of process and temperature variations. The compensation circuit draws a small current from the gate of the drive transistor to the first potential that is dependent upon process and temperature variations of the drive transistor, and therefore reduces the discharge rate of the gate of the drive transistor according to process and temperature variations of the drive transistor. II), wherein (a) A1 is an amino acid sequence of 7 to 8 amino acid residues; (b) A2 is an amino acid sequence; (c) A3 is an amino acid sequence of 3 amino acid residues and has the sequence Glu-A3a-A3b,wherein A3aand A3bare independently selected amino acid residues; (d) A4 is an amino acid sequence having a net anionic charge; (e) A5 is an amino acid sequence of 3 to 4 amino acid residues; (f) A6 is an amino acid sequence; (g) A7 is an amino acid residue selected from the group consisting of Val and Ile; (h) A8 is an amino acid sequence of 11 to 12 amino acid residues and includes an amino acid sequence selected from the group consisting of TBL Gly-Phe-Tyr-Arg-Asp, (SEQ. ID. NO. 69)Gly-Phe-Tyr-Arg-Asn, (SEQ. ID. NO. 70)Gly-Tyr-Tyr-Arg-Asp, (SEQ. ID. NO. 71)Gly-Tyr-Tyr-Arg-Asn, and (SEQ. ID. NO. 72)Gly-Leu-Tyr-Arg-Asp; (SEQ. ID. NO. 73) (i) A9 is an amino acid sequence of 5 to 7 amino acid residues; and (j) A10 is an amino acid sequence and includes an amino sequence selected from the group consisting of TBL Glu-Ile-Ile-His-Val, (SEQ. ID. NO. 74)Asp-Ile-Ile-Met-Val, (SEQ. ID. NO. 75)Phe-Ile-Thr-Phe-Ala-Pro, and (SEQ. ID. NO. 76)Met-Glu-Ile-Ile-Thr, (SEQ. ID. NO. 77) wherein each of A2, A4, A6 and A10 has an independently selected number of independently selected amino acid residues and each sequence is selected such that each NAP domain has in total less than about 120 amino acid residues and the protein has a NAP domain having an amino acid sequence substantially the same as the NAP domain of AcaNAPS (SEQ. ID. NO. 40). 6. An isolated protein having anticoagulant activity and having one or more NAP domains, wherein each NAP domain includes the sequence: Cys-A1-Cys-A2-Cys-A3-Cys-A4-Cys-A5-Cys-A6-Cys-A7-Cys-A8-Cys-A9-Cys-A10 (FORMULA II), wherein (a) A1 is an amino acid sequence of 7 to 8 amino acid residues; (b) A2 is an amino acid sequence; (c) A3 is an amino acid sequence of 3 amino acid residues and is selected from the group consisting of TBL Glu-Ala-Lys,Glu-Arg-Lys,Glu-Pro-Lys,Glu-Lys-Lys,Glu-Ile-Thr,Glu-His-Arg,Glu-Leu-Lys, andGlu-Thr-Lys; (d) A4 is an amino acid sequence having a net anionic charge; (e) A5 is an amino acid sequence of 3 to 4 amino acid residues; (f) A6 is an amino acid sequence; (g) A7 is an amino acid residue selected from Val or Ile; (h) A8 is an amino acid sequence of 11 to 12 amino acid residues and includes an amino acid sequence selected from the group consisting of TBL A8a-A8b-Gly-Phe-Tyr-Arg-Asp, (SBQ. ID. NO. 78)A8a-A8b-Gly-Phe-Tyr-Arg-Asn, (SBQ. ID. NO. 79)A8a-A8b-Gly-Tyr-Tyr-Arg-Asp, (SEQ. ID. NO. 80)A8a-A8b-Gly-Tyr-Tyr-Arg-Asn, (SEQ. ID. NO. 81)andA8a-A8b-Gly-Leu-Tyr-Arg-Asp, (SEQ. ID. NQ. 82) wherein at least one of A8aand A8bis Glu or Asp; (i) A9 is an amino acid sequence of 5 amino acid residues; and (j) A10 is an amino acid sequence and includes an amino acid sequence selected from the group consisting of Glu-Ile-Ile-His-Val (SEQ. ID. NO. 74), Asp-Ile-Ile-Met-Val (SEQ. ID. NO. 75), Phe-Ile-Thr-Phe-Ala-Pro (SEQ. ID. NO. 76), and Met-Glu-Ile-Ile-Thr (SEQ. ID. NO. 77) wherein each of A2, A4, A6 and A10 has an independently selected number of independently selected amino acid residues and each sequence is selected such that each NAP domain has in total less than about 120 amino acid residues, and wherein the protein has a NAP domain substantially the same as a NAP domain of AcaNAP5 (SEQ. ID. NO. 40). 7. A pharmaceutical composition comprising the protein of claim 4. 8. A pharmaceutical composition comprising the protein of claim 5. 9. A pharmaceutical composition comprising the protein of claim 6. 10. A method of inhibiting blood coagulation comprising administering a protein of claim 4 with a phar maceutically acceptable carrier. 11. A method of inhibiting blood coagulation comprising administering a protein of claim 5 with a pharmaceutically acceptable carrier. 12. A method of inhibiting blood coagulation comprising administering a protein of claim 6 with a pharmaceutically acceptable carrier.